Study guide
6.4 Communicating with Prescribers & Documenting Changes
APC Intern Written Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Pathway to General Registration 1.3 Restricted Open-Book Strategy (AMH & APF) 1.4 Scoring, Results & Appeals
2 Legal Framework: PBS & Medicine Schedules
2.1 PBS, Authority Prescriptions & Special Access Scheme 2.2 Schedules 2 & 3 (Pharmacy & Pharmacist Only Medicines) 2.3 Schedules 4 & 8 (Prescription Only & Controlled Drugs)
3 Legal Framework: Privacy, National Law & Pharmacy Board
3.1 Privacy, Confidentiality & Patient Rights 3.2 Health Practitioner National Law & Registration 3.3 Pharmacy Board Codes, Guidelines & Standards
4 Patient-Centred Medication Management
4.1 Assessing Clinical Situations & Treatment Options 4.2 Patient Factors: Adherence, Efficacy & Safety 4.3 Drug & Dosage-Form Factors 4.4 Culturally Responsive Medication Management
5 Primary Care & Judicious Use of Medicines
5.1 Primary Care & OTC Assessment 5.2 Judicious Use of Antimicrobials & High-Risk Agents 5.3 Non-Pharmacological Options & Evidence-Based OTC Choices
6 Dispensing & Clinical Appropriateness
6.1 Prescription Evaluation 6.2 Clinical Appropriateness Checks 6.3 Labelling, Packaging & Dispensing Standards 6.4 Communicating with Prescribers & Documenting Changes
7 Counselling & Acute Care
7.1 Patient-Centred Counselling 7.2 Confirming Understanding & Lifestyle Counselling 7.3 Acute Illness, Injury & Emergency Response
8 Therapeutics: Cardiovascular & Endocrine
8.1 Hypertension & Heart Failure 8.2 Ischaemic Heart Disease & Anticoagulation 8.3 Diabetes Medicines 8.4 Thyroid & Lipid Disorders
9 Therapeutics: Infection, Respiratory & Gastrointestinal
9.1 Anti-Infectives & Infection Management 9.2 Asthma & COPD 9.3 Gastrointestinal & Hepatic Conditions 9.4 Vaccination & Travel Health
10 Therapeutics: Neurology, Psychiatry & Pain
10.1 Epilepsy & Movement Disorders 10.2 Depression, Anxiety & Psychosis 10.3 Pain Management & Opioids 10.4 Migraine & Common Analgesics
11 Therapeutics: Special Populations & Systems
11.1 Women's Health, Contraception & Pregnancy 11.2 Dermatology, Ophthalmology & ENT 11.3 Renal/Hepatic Impairment & Dose Adjustment
12 Therapeutics: Rheumatology, Haematology, Urology, Oncology & Toxicology
12.1 Rheumatology: Gout, Osteoarthritis & Inflammatory Arthritis 12.2 Haematology: Anaemias & Blood Safety Monitoring 12.3 Urology & Men's Health 12.4 Oncology Support & Oral Anticancer Medicines 12.5 Toxicology & Poisoning Management
13 Monitoring: Clinical Review
13.1 Clinical Review Process 13.2 Interpreting Laboratory & Clinical Monitoring 13.3 Recommending Treatment Modifications
14 Monitoring: Safety & Adverse Drug Reactions
14.1 Adverse Drug Reactions & Reporting 14.2 Allergies, Sensitivities & Cross-Reactivity 14.3 High-Risk Medicines Monitoring
15 Compounding Medicines
15.1 Determining Required Formulations 15.2 Compounding Standards & Quality 15.3 Patient-Specific Preparations
16 Pharmaceutical Calculations
16.1 Dosage Calculations 16.2 Concentrations, Dilutions & Alligation 16.3 Half-Life & Basic Kinetic Calculations
17 Promote Health & Well-Being
17.1 National & Local Health Priorities 17.2 Screening Programs & Pharmacist Role 17.3 Culturally Responsive Promotion & Self-Sufficiency
6.4 Communicating with Prescribers & Documenting Changes
Key Takeaways Explain This Topic AI
Professional assertiveness means clearly stating the patient-safety issue and the requested action without aggression or inappropriate deference.
SBAR-style structure (Situation, Background, Assessment, Recommendation) keeps prescriber calls concise and clinically useful under time pressure.
Withhold supply when legality or critical safety is unresolved; urgency does not convert an unsafe script into a safe one.
Document interventions, agreed changes, and amended directions so the record matches what was supplied and counselled.
Escalate persistent patient-safety risk through appropriate clinical and professional channels while maintaining collaborative care.
Last updated: August 2026
6.4 Communicating with Prescribers & Documenting Changes
Quick Answer: If evaluation or clinical checks fail, contact the prescriber with a clear safety message, recommended action, and timeframe. Use a structured approach (SBAR-style), withhold supply when risk or legality is unresolved, document what was agreed, amend directions only through a lawful pathway, and escalate if patient safety remains at risk. Collaboration is professional — it is not rubber-stamping unsafe orders.
Dispensing competence includes interprofessional communication . Many Intern Written stems are decided not by drug monographs alone, but by whether you choose an appropriate communication and documentation pathway.
Why communication is part of Standard 3.2.3
You will regularly find:
- Missing prescription particulars
- Ambiguous doses
- Allergy conflicts
- Interaction or duplication problems
- Renal dose mismatches
- Patient reports that differ from the written plan
- Monitoring results that make the current dose unsafe
In each case, the pharmacist’s duty is to protect the patient and maintain a defensible record. Silence, guessing, or “the doctor will sort it later” after full supply is not acceptable when critical risk is present.
Professional assertiveness
Professional assertiveness sits between two failure modes:
- Failure mode Behaviour Risk
- Passive Dispense despite concern to avoid conflict Patient harm; professional liability
- Aggressive Accusatory, disrespectful, or obstructive without options Damaged collaboration; poorer outcomes
Assertive (goal) Clear, respectful, evidence-informed, solution-focused Safer care; durable working relationships
Assertive language patterns:
- “I am calling because I have a safety concern about…”
- “The patient’s record shows… which conflicts with…”
- “My recommendation is to… Alternatives could include…”
- “I will withhold supply until we confirm…”
Avoid:
- “You made a mistake” as an opening (focus on the clinical issue)
- Hiding the concern in vague small talk until the end of the call
- Accepting an unsafe instruction solely because of hierarchy or time pressure
Hierarchy does not outrank patient safety or legal supply requirements . Specialists and senior medical staff can still receive appropriate pharmacist challenges when evidence supports concern.
SBAR-style communication
SBAR is widely used in healthcare handovers. Adapted for pharmacist–prescriber calls:
S — Situation
One sentence: who you are, who the patient is, and the immediate issue.
“This is Priya, pharmacist at Harbour Pharmacy, calling about Sam Lee’s new prescription for drug X — I have a concern about the dose given the recorded eGFR.”
B — Background
Brief relevant facts only: age, key conditions, current medicines, allergy, pregnancy status, what the script says, recent labs if known.
“Sam is 79 with CKD; eGFR was 28 last month. Regular medicines include an ACE inhibitor. The new script is full-dose drug X daily.”
A — Assessment
Your professional interpretation.
“At this renal function, AMH suggests a reduced dose / increased interval; full dose risks accumulation and toxicity. There is also additive renal risk with the NSAID on file.”
R — Recommendation
Specific ask and interim plan.
“I recommend reducing to [dose] and reviewing the NSAID. I am withholding full-dose supply for now. Can you confirm an amended dose today?”
Why SBAR helps in exams and practice: it forces prioritisation, reduces rambling, and makes the “what do you want the prescriber to do?” explicit — which is often what distinguishes a high-scoring action option.
- Communication channels
- Phone for urgent clinical/legal blocks
- Secure messaging / e-prescription amendment pathways where available
- Written confirmation when changes are complex
- Avoid relying on the patient as the sole messenger for critical dose changes
- When to withhold supply
Withholding (or delaying) supply is appropriate when:
Prescription is legally incomplete or inauthentic
Critical clinical risk is unresolved (severe allergy match, major interaction, apparent overdose, pregnancy contraindication, anticoagulant duplication)
- S8/monitored medicine requirements are not met
- Patient identity cannot be reasonably confirmed
- Cold-chain or product integrity is compromised and no safe alternative stock exists
The patient refuses essential counselling for a high-risk medicine and cannot use it safely (context-dependent judgement)
Withholding is not abandonment. Explain the reason in plain language, assess interim risk (e.g. seizure medicines, insulin, transplant immunosuppressants), and escalate urgently to obtain a safe plan. For time-critical therapies, prioritise rapid prescriber contact and consider emergency legal pathways recognised in your jurisdiction only when they truly apply — do not invent emergency powers.
Partial information strategy
Sometimes you can supply an interim safe option after agreement (short quantity, reduced dose as amended, alternative agent). Never create a permanent therapy change without prescriber authority except where specific pharmacist prescribing/structured collaborative arrangements lawfully allow it.
Documenting interventions
If it is not documented, it is difficult to defend, hand over, or claim that care occurred. Document:
- Date/time and pharmacist identity
- Issue identified (legal and/or clinical)
- Information sources (patient report, eGFR value, allergy history, AMH check)
- Who was contacted (prescriber name/role) and how
- Advice given and options discussed
- Agreed outcome (amended dose, cancelled item, monitoring plan, no change with rationale)
- What was supplied (including partial/owing)
- Patient counselling points related to the change
- Follow-up actions (recall, lab check, next contact)
Keep records factual and professional. Avoid pejorative comments about the prescriber. Privacy rules still apply — document what is needed for care and accountability.
Agreed changes and amended directions
When the prescriber agrees to a change:
Confirm the new drug/strength/dose/quantity/duration clearly
Ensure the prescription record is amended through a lawful mechanism (new prescription, compliant electronic amendment, or jurisdiction-accepted annotation process — especially strict for S8)
- Update the dispensing system so the label matches the agreed regimen
- Destroy or quarantine incorrect labels/products prepared under the old directions
- Counsel the patient on what changed and why , including old pack disposal if relevant
Communicate changes to other carers/facilities when appropriate (e.g. dose administration aid packing service, residential aged care)
Critical rule: do not permanently change a prescribed regimen based only on patient preference without prescriber involvement when the medicine is prescription-only and the change is clinically material. Do not “quietly” alter directions on the label while leaving the legal prescription and claim inconsistent.
Examples of acceptable vs unacceptable amendment practice
Scenario Acceptable pathway Unacceptable shortcut
Dose too high in renal impairment Prescriber agrees reduced dose; script amended; label matches Pharmacist unilaterally quarters tablets long-term without authority
- Missing strength Prescriber confirms strength; complete prescription obtained Guess common strength and supply
- Brand substitution Within PBS/professional rules and patient consent Substitute non-equivalent product
Patient wants to stop medicine Discuss, then involve prescriber for planned cessation when needed Advise abrupt stop of high-risk medicine without plan
Escalation if patient safety risk persists
If the prescriber is uncontactable, dismissive without addressing the clinical evidence, or insists on a course you reasonably believe is seriously unsafe or illegal:
- Re-state the concern with evidence and proposed safer alternatives
- Withhold if legal/critical safety threshold is not met
Seek a second clinical opinion pathway appropriate to setting (another authorised prescriber involved in care, hospital team, senior pharmacist/clinical lead)
For suspected diversion, forgery, or criminality, follow legal reporting and non-supply obligations
For ongoing professional conduct concerns, understand Board notification pathways exist for serious risk — used judiciously, not as a first response to ordinary clinical disagreement
Document every step and the reason supply did or did not proceed
Escalation is about risk , not winning an argument.
Collaborative care mindset
Effective pharmacist–prescriber relationships improve outcomes:
- Share monitoring results and adherence barriers
- Offer practical alternatives (formulations, PBS-available strengths, simpler regimens)
Acknowledge diagnostic uncertainty when you lack the full medical picture — ask for the missing piece rather than overclaiming
Close the loop: after an agreed change, confirm the patient understands and that packing services/other pharmacies are not still supplying the old plan
Respect scope: recommend and question; do not present recommendations as orders to medical colleagues, and do not accept illegal orders as “collaboration”
Collaboration includes the patient . Explain why you are contacting the doctor, what you are recommending, and what happens next. Patients who understand the safety reason are less likely to pressure unsafe supply.
- Integrated communication workflow
- Detect issue (legal evaluation or clinical check)
- Decide urgency and whether interim partial supply is safe
- Prepare SBAR facts and preferred options (AMH-supported)
- Contact prescriber via appropriate channel
- Agree plan or escalate
- Lawfully amend prescription/records
- Label, pack, counsel to the new plan
- Document intervention and follow-up
- Exam mindset
High-yield stems often offer four options: dispense as written; change label unilaterally; contact/withhold with structured recommendation; or ignore because “doctor knows best.” The best answer almost always preserves legal supply authority + patient safety + documentation , using assertive structured communication rather than silence or unilateral guesswork.